acneiform eruption
Conditions
Interventions
Treatment: topical benzoyl peroxide once daily to acneiform eruption for 8 weeks
Sponsors
Tohoku University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Either patient who meet one of the following criteria ((a)(b)(c). (a)Patients who have non-small cell carcinoma and have received EGFR inhibitors (erlotinib, afatinib, gefitinib).EGFR inhibitors is scheduled to continue for more than 8 weeks. (b)Patients who have colorectal cancer and have received EGFR inhibitors (cetuximab, panitumumab).EGFR inhibitors is scheduled to continue for more than 8 weeks. (c)Patients who have head and neck cancer and have received EGFR inhibitors (cetuximab).EGFR inhibitors is scheduled to continue for more than 8 weeks. (2)Patients, who diagnosed as acneiform eruption and received treatment of topical steroid with or without oral tetracycline, persist the eruption on the face even after 10 or more weeks after the start of EGFR inhibitors. (3) ECOG performance status (PS) at the time of registration is 0 pr 1.
Exclusion criteria
Exclusion criteria: (1)Oral tetracycle (MINO or DOXY) has been started within 4 weeks for the treatment of acneiform eruption. (2)Oral steroids are administrated for the treatment of acneiform eruption. (3)Patient has skin lesion of skin metastatic lesions, burns, frostbite, trauma, scars and/or other lesions to be difficult to evaluate skin symptoms on the test area. (4)Patient has erosions, wounds, etc. that are problematic in applying benzoyl peroxide: BPO gel to the test area. (5)Patient has a history of hypersensitivity to BPO. (6)Pregnant women, women who has possibility of pregnant, woman within 28 days after childbirth, or woman who in breastfeeding. (7)Patient who is considered to have difficulty participating in research by merging psychosis or psychiatric symptoms. (8)Patient who researchers deem that research participation is inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity grade of acneiform eruption on the face before and 8 weeks after the test treatment | — |
Countries
Japan
Contacts
Public ContactKatsuko Kikuchi
Tohoku University Hospital Dermatology
Outcome results
None listed